GlassScriptPhysician profile
Laura Selman
NPI 1437780608
$4,144.88
in general payments reported to CMS, 2019-2025
31 companies · $811 in 2025
The $811 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $241 · 2022: $744 · 2023: $1,256 · 2024: $1,094 · 2025: $811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,160.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $765.90 | 2021-2025 | |
| Pfizer INC. | $319.54 | 2021-2025 | |
| Amgen INC. | $315.57 | 2022-2025 | Otezla, Otezla |
| Genzyme Corporation | $304.29 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $298.74 | 2021-2024 | Dupixent, Libtayo |
| Janssen Biotech, INC. | $229.50 | 2022-2025 | Tremfya, Simponi, Simponi Aria |
| Dermavant Sciences, INC. | $198.69 | 2023-2024 | Vtama |
| Ucb, INC. | $168.81 | 2022-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $144.61 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $141.98 | 2022-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $141.97 | 2021-2025 | Ebglyss, Taltz |
| E.R. Squibb & Sons, L.L.C. | $130.19 | 2022-2024 | Sotyktu |
| Journey Medical Corporation | $123.64 | 2022-2025 | |
| Incyte Corporation | $119.02 | 2022-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $115.67 | 2022-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $94.32 | 2023-2024 | Arazlo, Jublia, Cabtreo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.86 | 2023-2025 | Spevigo |
| Galderma Laboratories, L.P. | $66.13 | 2022-2025 | Nemluvio, Oracea, Epsolay |
| Mayne Pharma Commercial LLC | $61.76 | 2023 | |
| Sun Pharmaceutical Industries INC. | $60.46 | 2022-2024 | Ilumya, Winlevi, Absorica Ld |
| Almirall LLC | $58.49 | 2023 | Klisyri |
| Organon LLC | $32.45 | 2025 | |
| Verrica Pharmaceuticals INC. | $24.46 | 2023 | Ycanth |
| Ferring Pharmaceuticals INC. | $21.08 | 2021 | |
| Medimetriks Pharmaceuticals, INC. | $20.39 | 2025 | Genadur |
| Botanix Sb INC | $19.72 | 2025 | Sofdra |
| Organogenesis INC. | $19.51 | 2024 | |
| Kyowa Kirin, INC. | $19.50 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $19.10 | 2023 | Valchlor |
| Merck Sharp & Dohme LLC | $17.35 | 2021 | |
| Genentech USA, INC. | $14.18 | 2024 | Erivedge |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Selman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.